GLSI News and Press, Greenwich LifeSciences Inc. From 02/10/22

Greenwich LifeSciences (GLSI +24.4%) is enjoying substantial gains Thursday, continuing a winning streak that began on Tuesday. From the close of trading Monday through Wednesday's close, shares rose ~11%. Year to date through Wednesday's close, shares are down 16%. The recent ...

Gainers: Dermata (NASDAQ:DRMA) +25%. IronNet (NYSE:IRNT) +25%. China Online Education (NYSE:COE) +25%. Greenwich LifeSciences (NASDAQ:GLSI) +25%. CleanSpark (NASDAQ:CLSK) +24%. Ebang International Holdings (NASDAQ:EBON) +22%. Lufax Holding (NYSE:LU) +22%. Vaccinex (NASDAQ:VCNX) +21%. The Vale...

Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of GLSI-100, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery, today announced that Sne...

Greenwich LifeSciences (NASDAQ:GLSI) provides an update on the Phase III clinical trial, FLAMINGO-01. The combination of GP2 + GM-CSF will be called GLSI-100. The Phase III trial is comprised of 2 placebo-controlled arms for approx. 500 HLA-A*02 patients and 1 open label arm of up to 100 pati...

- The GP2 Phase III clinical trial poster was presented in person at the 2021 annual San Antonio Breast Cancer Symposium (SABCS). The Company was a SABCS sponsor and held a clinical trial planning meeting with investigators at the conference. The poster can be seen here . - Crit...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips This article is excerpted from Tom Yeung’s Moonshot Investor newsletter. To make sure you don’t miss any of Tom’s potential 100x picks, subscribe to his mailing list here . Markets Go Up, Sentiment...

Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of GLSI-100, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery, today announced that its...

Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of GLSI-100, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery, today announced that CEO...

Greenwich LifeSciences (NASDAQ:GLSI) announces the publication of the GP2 Phase IIb clinical trial at the San Antonio Breast Cancer Symposium 2021 (SABCS). The trial enrolled HER2 positive patients, who received a standard course of trastuzumab after surgery, and HER2 low patients, who did no...

Identifying GP2 specific T cell immune response at baseline prior to treatment with GP2 has potential to predict breast cancer recurrence risk and timing of recurrence A positive baseline immune response to GP2 in 22.8% of 145 patients suggests an existing immune response to GP2 a...